NCT00388583已完成2 期
Immunogenicity and Safety of The Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Ambulatory Elderly Subjects
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 817
- 试验地点
- 17
- 主要终点
- Number of Participants With at Least a 4-Fold Increase in Serum HAI Antibody Titer Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine.
研究概览
简要总结
As a result of the safety and immunogenicity data generated from earlier dose-ranging studies, the present formulation has been selected for further development in the elderly.
Primary Objective:
To compare the immunogenicity in subjects receiving investigational Fluzone with those of subjects receiving standard Fluzone®.
Secondary Objectives:
Immunogenicity:
To describe the immunogenicity in subjects receiving investigational Fluzone and standard Fluzone®.
Safety:
To evaluate and describe the safety profile of investigational Fluzone in terms of solicited- and unsolicited adverse events and serious adverse events post-vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged ≥ 65 years on the day of vaccination.
- •Informed consent form signed.
- •Medically stable (Subjects may have underlying illnesses such as hypertension, diabetes, ischemic heart disease, congestive cardiac disorders or hypothyroidism, as long as their symptoms/signs are controlled).
- •Able to attend all scheduled visits and to comply with all trial procedures.
排除标准
- •Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or a history of a life-threatening reaction to the standard-dose Fluzone® vaccine or a vaccine containing the same substances (the list of vaccine components is included in the Investigator's Brochure).
- •Congenital or history of acquired immunodeficiency, or immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months.
- •Systemic corticosteroid therapy as follows:
- •Continuous use with a dosage equivalent to > 15 mg/day of oral prednisone for 90 days preceding vaccination
- •Sporadic use with a dose of > 40 mg/day of oral prednisone for > 14 days in the 90 days preceding vaccination.
- •Note: Use of topical or inhalant corticosteroids is acceptable.
- •Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy, as well as subjects who have a history of neoplastic disease and who have been disease-free for ≥ 5 years).
- •Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures.
- •Receipt of blood or blood-derived products in the past 3 months.
- •Vaccination against influenza in the past 6 months.
- •Any vaccination in the 4 weeks preceding the trial vaccination.
- •Vaccination planned in the 4 weeks following the trial vaccination.
- •Participation in another clinical trial in the 4 weeks preceding trial vaccination.
- •Planned participation in another clinical trial during the present trial period. Concomitant participation in an observational trial (not involving drugs, vaccines, or medical devices) is acceptable.
- •Chronic illness at a stage that could interfere with trial conduct or completion.
- •Known current HIV, hepatitis B (HBsAg) or hepatitis C infection or seropositivity.
- •Known thrombocytopenia or bleeding disorder contraindicating IM vaccination.
- •Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
- •Acute illness and febrile illness with a temperature ≥ 38.0°C [or 100.4°F]) 72 hours before or on the day of inclusion.
- •Received antibiotics therapy within 72 hours preceding the trial vaccination.
- •Received any allergy shots in the 7-day period preceding trial vaccination and/or scheduled to receive any allergy shots in the 7-day period after trial vaccination.
- •Any condition, which in the opinion of the investigator would pose a health risk to the participant.
结局指标
主要结局
Number of Participants With at Least a 4-Fold Increase in Serum HAI Antibody Titer Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine.
时间窗: Pre-vaccination and Day 28 post-vaccination
The serological determinations of total anti-influenza antibodies were performed using an Hemagglutinin inhibition (HAI) test.
Number of Participants Who Achieved Seroprotection Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine.
时间窗: Day 28 post-vaccination
Seroprotection was defined as a post-vaccination Hemagglutinin inhibition (HAI) antibody titer ≥ 40
次要结局
- Geometric Mean Antibody Titers (GMTs) Before and Post-vaccination With Either Fluzone Intradermal and Fluzone Intramuscular Vaccine.(Pre- and Day 28 post-vaccination)
- Number of Participants Reporting a Solicited Injection Site or Systemic Reaction, Post Vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine(Day 0 up to 7 days post-vaccination)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
2 期
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in InfantsInfluenzaNCT01494740Shanghai Institute Of Biological Products312
已完成
2 期
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy AdultsInfluenzaNCT00328107Protein Sciences Corporation459
已完成
不适用
Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/ElderlyInfluenzaNCT02313740Butantan Institute120
已完成
3 期
Safety and immunogenicity of rabies vaccines in animal bite cases administered using new one week intradermal regimeCTRI/2012/12/003230Department of Community Medicine Kempegowda Institute of Medical Sciences KIMS80
进行中（未招募）
不适用
CLOSTRIDIUM DIFFICILE study to confirm the best vaccine dose, to evaluate immune system response, and to collect safety information about VLA84. The study treatment groups are assigned randomly, it is placebo controlled and safety evaluation is performed blinded.EUCTR2014-003934-22-DEValneva Austria GmbH500